Literature DB >> 30118349

Inhibition of autotaxin alleviates inflammation and increases the expression of sodium-dependent glucose cotransporter 1 and Na+/H+ exchanger 3 in SAMP1/Fc mice.

Peijian He1,2, Abedul Haque1,2, Songbai Lin1,2, Fabio Cominelli3, C Chris Yun1,2,4.   

Abstract

Crohn's disease (CD) is a chronic, relapsing, inflammatory disease that is often associated with malnutrition because of inflammation in the small intestine. Autotaxin (ATX) is a secreted enzyme that produces extracellular lysophosphatidic acid. Increasing evidence suggests that ATX is upregulated during inflammation, and inhibition of ATX has been effective in attenuating chronic inflammatory conditions, such as arthritis and pulmonary fibrosis. This study aims to determine whether inhibition of ATX alleviates CD-associated inflammation and malnutrition by using SAMP1/Fc mice, a model of CD-like ileitis. SAMP1/Fc mice were treated the ATX inhibitor PF-8380 for 4 wk. Inhibition of ATX led to increased weight gain in SAMP1/Fc mice, decreased T helper 2 cytokine expression, including IL-4, IL-5, and IL-13, and attenuated immune cell migration. SAMP1/Fc mice have low expression of Na+-dependent glucose transporter 1 (SGLT1), suggesting impaired nutrient absorption associated with ileitis. PF-8380 treatment significantly enhanced SGLT1 expression in SAMP1/Fc mice, which could reflect the increased weight changes. However, IL-4 or IL-13 did not alter SGLT1 expression in Caco-2 cells, ruling out their direct effects on SGLT1 expression. Immunofluorescence analysis showed that the expression of sucrase-isomaltase, a marker for intestinal epithelial cell (IEC) differentiation, was decreased in inflamed regions of SAMP1/Fc mice, which was partially restored by PF-8380. Moreover, expression of Na+/H+ exchanger 3 was also improved by PF-8380, suggesting that suppression of inflammation by PF-8380 enhanced IEC differentiation. Our study therefore suggests that ATX is a potential target for treating intestinal inflammation and restoration of the absorptive function of the intestine. NEW & NOTEWORTHY This study is the first, to our knowledge, to determine whether autotoxin (ATX) inhibition improves inflammation and body weights in SAMP1/Fc mice, a mouse model of ileitis. ATX inhibition increased body weights of SAMP1/Fc mice and increased Na+-dependent glucose transporter 1 (SGLT1) expression. Increased SGLT1 expression in the inflamed regions was not a direct effect of cytokines but an indirect effect of increased epithelial cell differentiation upon ATX inhibition.

Entities:  

Keywords:  Na-dependent glucose transporter 1; Na/H exchanger 3; autotaxin; inflammatory bowel diseases

Mesh:

Substances:

Year:  2018        PMID: 30118349      PMCID: PMC6293258          DOI: 10.1152/ajpgi.00215.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  70 in total

1.  Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease.

Authors:  M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

Review 3.  Autotaxin inhibitors: a patent review (2012-2016).

Authors:  Aikaterini Nikolaou; Maroula G Kokotou; Dimitris Limnios; Anastasia Psarra; George Kokotos
Journal:  Expert Opin Ther Pat       Date:  2017-05-09       Impact factor: 6.674

4.  IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells.

Authors:  J Laoukili; E Perret; T Willems; A Minty; E Parthoens; O Houcine; A Coste; M Jorissen; F Marano; D Caput; F Tournier
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.

Authors:  James Gierse; Atli Thorarensen; Konstantine Beltey; Erica Bradshaw-Pierce; Luz Cortes-Burgos; Troii Hall; Amy Johnston; Michael Murphy; Olga Nemirovskiy; Shinji Ogawa; Lyle Pegg; Matthew Pelc; Michael Prinsen; Mark Schnute; Jay Wendling; Steve Wene; Robin Weinberg; Arthur Wittwer; Ben Zweifel; Jaime Masferrer
Journal:  J Pharmacol Exp Ther       Date:  2010-04-14       Impact factor: 4.030

6.  Mechanism of inhibition of Na+-glucose cotransport in the chronically inflamed rabbit ileum.

Authors:  U Sundaram; S Wisel; V M Rajendren; A B West
Journal:  Am J Physiol       Date:  1997-10

7.  Anti-interleukin-12 antibody for active Crohn's disease.

Authors:  Peter J Mannon; Ivan J Fuss; Lloyd Mayer; Charles O Elson; William J Sandborn; Daniel Present; Ben Dolin; Nancy Goodman; Catherine Groden; Ronald L Hornung; Martha Quezado; Zhiqiong Yang; Markus F Neurath; Jochen Salfeld; Geertruida M Veldman; Ullrich Schwertschlag; Warren Strober
Journal:  N Engl J Med       Date:  2004-11-11       Impact factor: 91.245

8.  Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.

Authors:  Jian-Min Wu; Yan Xu; Nicholas J Skill; Hongmiao Sheng; Zhenwen Zhao; Menggang Yu; Romil Saxena; Mary A Maluccio
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

9.  Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.

Authors:  Iqbal Siddique; Fuad Hasan; Islam Khan
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

10.  Distinct phospholipase C-β isozymes mediate lysophosphatidic acid receptor 1 effects on intestinal epithelial homeostasis and wound closure.

Authors:  Sei-Jung Lee; Giovanna Leoni; Philipp-Alexander Neumann; Jerold Chun; Asma Nusrat; C Chris Yun
Journal:  Mol Cell Biol       Date:  2013-03-11       Impact factor: 4.272

View more
  1 in total

Review 1.  The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin-lysophosphatidic acid as a new therapeutic target?

Authors:  Felipe S Gallardo; Adriana Córdova-Casanova; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2021-03-10       Impact factor: 5.782

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.